Andere Sprachen Shuttle Pharmaceuticals Holdings, Inc.

Aktien

A3DMNY

US8256932034

SHPH

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 24.05.2024			% 5 Tage	% 1. Jan.
0.4149 ^USD	-2.72%		+3.60%	-8.81%

21.03.	Shuttle Pharmaceuticals Holdings, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
08.01.	Shuttle Pharmaceuticals erhält FDA-Genehmigung für klinische Phase II-Studie mit Ropidoxuridin zur Behandlung von Patienten mit Glioblastom	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024	22.05.
Shuttle Pharma Provides First Quarter 2024 Corporate Update	14.05.
Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024	23.04.
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024	03.04.
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update	25.03.
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update	22.03.
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024	05.03.
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering	13.02.
Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $2.25 million in funding	07.02.
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024	23.01.
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma	08.01.
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma	12.12.
Shuttle Pharmaceuticals Holdings, Inc. Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma	11.12.
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023	30.11.
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update	14.11.
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program through Exclusive License Agreement	01.11.
Shuttle Pharmaceuticals : Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement - Form 8-K	30.10.23
Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference	10.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Shuttle Pharmaceuticals Holdings, Inc.

Aktien

A3DMNY

US8256932034

SHPH

Andere Sprachen

Filter